Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 9
1960 25
1961 31
1962 42
1963 1
1964 7
1965 83
1966 179
1967 206
1968 222
1969 232
1970 229
1971 254
1972 254
1973 268
1974 303
1975 291
1976 342
1977 324
1978 305
1979 335
1980 343
1981 338
1982 268
1983 337
1984 400
1985 385
1986 420
1987 443
1988 480
1989 490
1990 496
1991 548
1992 542
1993 554
1994 583
1995 607
1996 581
1997 564
1998 570
1999 554
2000 538
2001 562
2002 514
2003 544
2004 483
2005 504
2006 476
2007 434
2008 456
2009 393
2010 469
2011 461
2012 383
2013 368
2014 370
2015 379
2016 324
2017 306
2018 304
2019 132
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

20,980 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety.
Busse LW, et al. Crit Care Med 2017 - Review. PMID 28489648 Free PMC article.
OBJECTIVE: Angiotensin II is an endogenous hormone with vasopressor and endocrine activities. This is a systematic review of the safety of IV angiotensin II. ...One healthy subject died after a pressor dose of angiotensin II was infused continuously for 6 days. No other serious adverse events attributable to angiotensin II were reported. ...
OBJECTIVE: Angiotensin II is an endogenous hormone with vasopressor and endocrine activities. This is a systematic review of t …
Angiotensin II decreases the rate of production of cerebrospinal fluid.
Maktabi MA, et al. Brain Res 1993. PMID 8462002
Circulating angiotensin II decreases blood flow to the choroid plexus. The first goal of this study was to examine the hypothesis that angiotensin II decreases the production of CSF. ...Rabbits received either vehicle, angiotensin II, angiotensin II in the presence of an angiotensin II antagonist (saralasin), or saralasin intravenously. ...
Circulating angiotensin II decreases blood flow to the choroid plexus. The first goal of this study was to examine the hypothe …
A comparison of the ability of two angiotensin II receptor blocking drugs, 1-Sar; 8-Ala angiotensin II and 1-Sar, 8-Ile angiotensin II, to modify the regulation of glomerular filtration rate in the cat.
Johns EJ. Br J Pharmacol 1980. PMID 7470759 Free PMC article.
The falls in absolute and fractional sodium excretions caused by this manoeuvre were of similar magnitude to those obtained in the absence of drug.5 The results obtained using the 1-Sar, 8-Ile angiotensin II are consistent with angiotensin II having an important intra-renal site of action to regulate glomerular filtration rate, possibly via an action at the efferent arteriole. Administration of 1-Sar, 8-Ala angiotensin II was without effect on the regulation of renal haemodynamics which it is suggested reflects a limitation in the use of this particular compound as an intrarenal angiotensin II antagonist....
The falls in absolute and fractional sodium excretions caused by this manoeuvre were of similar magnitude to those obtained in the absence o …
Cephalic angiotensin receptors mediating drinking to systemic angiotensin II.
Johnson AK and Schwob JE. Pharmacol Biochem Behav 1975. PMID 177996
In rats implanted with cannulae to allow delivery of solutions to the cerebral ventricular system, pretreatment with 5 mug or 0.5 mug of saralasin acetate (Sar1 Ala8 Angiotensin II), an angiotensin II competitive analog, significantly attenuated drinking to subcutaneous (SC) injections of 500 mug of angiotensin II. ...On the basis of the specificity and the greater efficacy shown by IC saralasin in attenuating drinking to systemically applied angiotensin II, it was concluded that circulating angiotensin II reaches brain periventricular receptors which mediate drinking....
In rats implanted with cannulae to allow delivery of solutions to the cerebral ventricular system, pretreatment with 5 mug or 0.5 mug of sar …
Angiotensin II antagonists.
Brunner HR, et al. Clin Exp Hypertens 1993 - Review. PMID 8268887
It is now possible to antagonize chronically angiotensin II at its receptor using the non-peptide angiotensin II inhibitor losartan (DuP 753, MK 954). When administered by mouth, this compound induces a dose-dependent inhibition of the pressor response to exogenous angiotensin II. ...
It is now possible to antagonize chronically angiotensin II at its receptor using the non-peptide angiotensin II
Angiotensin II dose-effect curves and Schild regression plots for characterization of different angiotensin II AT1 receptor antagonists in clinical pharmacology.
Belz GG. Br J Clin Pharmacol 2003 - Review. PMID 12848769 Free PMC article.
The original method was developed to quantitatively characterize antagonistic drugs in experimental pharmacology. The method was adopted for evaluation of various AT1 antagonists in humans utilizing (human) angiotensin II as the agonist. Angiotensin II (Ang II) in continuous intravenous dose-incremental administration resulted in a clearly dose-dependent increase in blood pressure. ...
The original method was developed to quantitatively characterize antagonistic drugs in experimental pharmacology. The method was adop …
Effects of angiotensin II on blood flow to choroid plexus.
Maktabi MA, et al. Am J Physiol 1990. PMID 2309908
The choroid plexus contains receptors for angiotensin II and a very high concentration of angiotensin-converting enzyme. The goal of this study was to test the hypothesis that angiotensin II decreases blood flow to the choroid plexus. ...Saralasin blocked the vasoconstrictor effect of angiotensin II on the choroid plexus and the kidney. Thus circulating angiotensin II has important and parallel effects on blood flow to the choroid plexus and kidney that are mediated by angiotensin II receptors. ...
The choroid plexus contains receptors for angiotensin II and a very high concentration of angiotensin-converting enzyme …
Dose-response curves for angiotensin II and synthetic analogues in three types of smooth muscle: existence of different forms of receptor sites for angiotensin II.
Papadimitriou A and Worcel M. Br J Pharmacol 1974. PMID 4371902 Free PMC article.
1 The dose-response curves for angiotensin II and four analogues in rat colon and uterus, and in rabbit aorta, were obtained.2 The ED(50) values of angiotensin II as well as the ED(50)s and intrinsic activities of angiotensin analogues varied between the three organs.3 The interaction of two competitive antagonists with angiotensin II receptors was also examined. The K(I) values obtained with both antagonists on the uterus differed from the values on the other tissues.4 It is concluded that angiotensin II receptors may be different in the three organs examined....
1 The dose-response curves for angiotensin II and four analogues in rat colon and uterus, and in rabbit aorta, were obtained.2 …
Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.
Hollenberg NK, et al. J Clin Invest 1976. PMID 1245602 Free PMC article.
We have assessed the capacity of an analogue of angiotensin II (A II), 1-Sar, 8-Ala A II (P113) in normal man to stimulate and block responses to A II in four systems: blood pressure was monitored directly from an arterial catheter, and renal blood flow was measured with 133Xe and arterial renin and aldosterone concentrations by radioimmunoassay. ...Higher P113 doses totally obliterated all three responses to A II infused at 10 ng/kg/min, a dose that provides arterial A II concentrations in the range found in angiotensin-mediated hypertension. ...
We have assessed the capacity of an analogue of angiotensin II (A II), 1-Sar, 8-Ala A II (P113) in normal man to …
20,980 results
Jump to page
Feedback